LifeStance Health Group (NASDAQ:LFST) COO Lisa Miller Sells 14,663 Shares of Stock

LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) COO Lisa Miller sold 14,663 shares of LifeStance Health Group stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $14.68, for a total value of $215,252.84. Following the sale, the chief operating officer directly owned 251,904 shares in the company, valued at $3,697,950.72. The trade was a 5.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

LifeStance Health Group Stock Performance

NASDAQ:LFST opened at $14.15 on Friday. The stock has a market cap of $5.38 billion, a P/E ratio of 74.48 and a beta of 1.35. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.17. The stock’s 50-day moving average is $12.77 and its 200-day moving average is $9.64. LifeStance Health Group, Inc. has a 1-year low of $6.01 and a 1-year high of $15.66.

LifeStance Health Group (NASDAQ:LFST – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $455.86 million during the quarter, compared to analyst estimates of $431.59 million. LifeStance Health Group had a net margin of 4.29% and a return on equity of 4.82%. The company’s revenue for the quarter was up 25.3% on a year-over-year basis. Equities research analysts anticipate that LifeStance Health Group, Inc. will post 0.18 earnings per share for the current year.

Hedge Funds Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently made changes to their positions in LFST. BlackRock Inc. bought a new position in LifeStance Health Group during the 2nd quarter worth approximately $389,293,000. Dimensional Fund Advisors LP lifted its position in shares of LifeStance Health Group by 16.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock worth $66,038,000 after purchasing an additional 1,461,215 shares during the period. Jennison Associates LLC boosted its stake in shares of LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after purchasing an additional 2,843,388 shares during the last quarter. Voya Investment Management LLC boosted its stake in shares of LifeStance Health Group by 1,249.6% in the 3rd quarter. Voya Investment Management LLC now owns 3,971,989 shares of the company’s stock valued at $47,783,000 after purchasing an additional 3,677,679 shares during the last quarter. Finally, Wellington Management Group LLP bought a new stake in shares of LifeStance Health Group in the 2nd quarter valued at $30,881,000. 85.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on LFST. Weiss Ratings restated a “hold (c)” rating on shares of LifeStance Health Group in a research report on Wednesday, November 4th. JPMorgan Chase & Co. lifted their price target on shares of LifeStance Health Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Thursday. BTIG Research lifted their price target on shares of LifeStance Health Group from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. KeyCorp boosted their price objective on shares of LifeStance Health Group from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. Finally, Wall Street Zen downgraded LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $14.86.

Check Out Our Latest Research Report on LFST

About LifeStance Health Group

(Get Free Report)

LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance’s clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.

Featured Stories

Insider Buying and Selling by Quarter for LifeStance Health Group (NASDAQ:LFST)

Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.